+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Handling uncertainty in cost-effectiveness models

Handling uncertainty in cost-effectiveness models

Pharmacoeconomics 17(5): 479-500

The use of modelling in economic evaluation is widespread, and it most often involves synthesising data from a number of sources. However, even when economic evaluations are conducted alongside clinical trials, some form of modelling is usually essential. The aim of this article is to review the handling of uncertainty in the cost-effectiveness results that are generated by the use of decision-analytic-type modelling. The modelling process is split into a number of stages: (i) a set of methods to be employed in a study are defined, which should include a 'reference case' of agreed methods to enhance the comparability of results; (ii) the clinical and demographic characteristics of the patients the model relates to should be specified as carefully as in any experimental study; and (iii) the data requirements of the model should be estimated using the principles of Bayesian statistics, such that prior distributions are specified for unknown model parameters. Monte Carlo simulation can then be employed to sample from these prior distributions to obtain a distribution of the cost effectiveness of the intervention. Such probabilistic analyses are related to parameter uncertainty. In addition, modelling uncertainty is likely to add a further layer of uncertainty to the results of particular analyses.

(PDF emailed within 0-6 h: $19.90)

Accession: 046211541

Download citation: RISBibTeXText

PMID: 10977389

DOI: 10.2165/00019053-200017050-00006

Related references

Handling Parameter Uncertainty in Cost-Effectiveness Models Simply and Responsibly. Medical Decision Making 35(5): 567-569, 2016

Handling Parameter Uncertainty in Cost-effectiveness Models Simply and Responsibly. Medical Decision Making, 2015

Uncertainty in decision models analyzing cost-effectiveness: the joint distribution of incremental costs and effectiveness evaluated with a nonparametric bootstrap method. Medical Decision Making 18(3): 337-346, 1998

Uncertainty in decision models analyzing cost-effectiveness. Medical Decision Making 20(1): 135-137, 2000

Uncertainty and variability in influenza cost-effectiveness models. Australian and New Zealand Journal of Public Health 35(6): 576; Author Reply 576-7, 2012

Structural and parameter uncertainty in Bayesian cost-effectiveness models. Journal of the Royal Statistical Society. Series C, Applied Statistics 59(2): 233-253, 2010

Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value in Health 8(1): 1-2, 2005

The impact of structural uncertainty on cost-effectiveness models for adjuvant endocrine breast cancer treatments: the need for disease-specific model standardization and improved guidance. Pharmacoeconomics 32(1): 47-61, 2014

How Does Uncertainty Around Costs And Effects Relate To Uncertainty Around Cost-Effectiveness?. Value in Health 17(7): A561-A562, 2014

Better informing decision making with multiple outcomes cost-effectiveness analysis under uncertainty in cost-disutility space. Plos One 10(3): E0115544-E0115544, 2016

Handling uncertainty in housing stock models. Building and Environment 48: 35-47, 2012

Handling uncertainty in dynamic transmission models. Vaccine 29(22): 3827; Author Reply 3828-3827; Author Reply 3828, 2011

Addressing uncertainty in medical cost-effectiveness analysis implications of expected utility maximization for methods to perform sensitivity analysis and the use of cost-effectiveness analysis to set priorities for medical research. Journal of Health Economics 20(1): 109-129, 2001

Uncertainty in cost-effectiveness analysis. Probabilistic uncertainty analysis and stochastic league tables. International Journal of Technology Assessment in Health Care 18(1): 112-119, 2002

Evidence Map of Cost-Benefit, Cost-Effectiveness and Cost-Utility Models In Dementia Published Since 1960. Value in Health 20(9): A724-A725, 2017